GLP-1 Advisor | One Day MD

Use GLP-1 correctly, with the evidence in front of you Independent, physician-written guides to semaglutide, tirzepatide and the new oral options. Choose a medicine to ask about, plan the cost, and track your progress privately. Compare your options Open the free tracker Sourced to U.S. FDA labeling. Every claim carries a CEBM evidence tier. We never recommend a dose. Quick Answer GLP-1 Advisor is an evidence-based guide to GLP-1 weight-management medicines. Start with the comparison guide, check cost and coverage, then use the free tracker once treatment begins. Your prescriber sets your dose. Where are you in your GLP-1 journey? Stage 1: Considering Which options should I ask about? Wegovy, Zepbound, and the daily pills, compared by goal, route and tolerability. Start GLP-1 weight loss in 2026 Pill or weekly injection? Stage 2: Starting What will it cost and who prescribes it? Prices, insurance coverage and ways to see a doctor. GLP-1 cost and coverage 2...

My GLP-1 Journey Track weight, doses and side effects privately. Everything stays in your own browser. Quick Answer: Set your plan once, log a weekly check-in, and watch your trend against your goal. Nothing is uploaded, and the tool never recommends a dose. Your plan Medication Start date Unit kg lb Starting weight Goal weight Save plan Progress Weight trend Log a check-in Date Weight Dose (mg) Side effects this week Notes Add entry History Typical dose-escalation schedules Medication Steps (mg, weekly) Usual interval Semaglutide (Ozempic) 0.25 → 0.5 → 1 → 2 4 weeks Semaglutide (Wegovy) 0.25 → 0.5 → 1 → 1.7 → 2.4 4 weeks Tirzepatide (Mounjaro/Zepbound) 2.5 → 5 → 7.5 → 10 → 12.5 → 15 4 weeks Dulaglutide (Trulicity) 0.75 → 1.5 → 3 → 4.5 4 weeks General label-based patterns for education only. Your prescriber sets your actual dose and pace. Medical disclaimer: This tool is for personal tracking and education, not medical advice. Cont...

By Dr. Frank Yap, MD  |  Published: September 28, 2026  |  Last updated: October 2026  |  Reference: U.S. FDA labeling  |  Purpose: evidence and safety education, not individual medical advice Quick Answer In the U.S. in 2026, adult weight-management GLP-1 options include Wegovy (weekly injection), Wegovy HD 7.2 mg (weekly, only after 2.4 mg is tolerated for 4+ weeks), the Wegovy pill (daily), Zepbound (tirzepatide, weekly) and Foundayo (orforglipron, daily pill). The only direct head-to-head trial, SURMOUNT-5, found -20.2% weight loss with tirzepatide vs -13.7% with semaglutide at 72 weeks, but pills and injections should not be ranked across different trials. Pick by goal (weight, heart risk, sleep apnea, liver), route, tolerability and cost, protect muscle with protein and resistance training, and plan for long-term maintenance because weight re...

Last reviewed: October 17, 2026 The obesity-treatment landscape has changed significantly with the arrival of oral GLP-1 medicines. People who previously had to choose between weekly injections, daily lifestyle changes, and other weight-management treatments now have additional prescription options. Two important oral treatments are Wegovy tablets (semaglutide 25 mg) from Novo Nordisk and Foundayo (orforglipron) from Eli Lilly. Both are taken daily, but they contain different active ingredients and have different administration requirements. Weekly injections remain important alternatives. These include standard-dose Wegovy, higher-dose Wegovy HD in the United States, and tirzepatide sold as Zepbound for weight management in the United States. Which option is best depends on the amount of weight loss needed, convenience, tolerability, other medical conditions, cost, and treatment availability. This guide compares the evidence without assuming that results from separate cl...